AlphaGenome brings DeepMind’s AI to non-coding DNA

Google DeepMind has introduced AlphaGenome, an artificial intelligence model designed to read large stretches of DNA and predict the biological consequences of small genetic variations. The tool can analyze sequences of up to one million base pairs — the chemical letters of DNA — and is aimed primarily at one of the hardest parts of the genome to interpret: non-coding DNA.

The announcement matters because most disease-associated variants are not found inside genes that produce proteins. Understanding what they do requires determining whether a mutation changes when, where or how strongly a gene is activated. AlphaGenome does not diagnose diseases or replace a laboratory experiment, but it aims to narrow down which variants should be researched first.

The problem lies in the 98% of the genome

Only about 2% of the human genome codes for proteins. The remaining 98% contains regulatory instructions: sequences that control gene activity depending on the cell type, tissue or stage of development. For decades, some of this territory was imprecisely referred to as “junk DNA.” It is now known to contain many important signals, although deciphering them remains a complex task.

A single variant may leave a protein unchanged and still have significant effects. It can alter RNA production — the molecule between DNA and protein — modify how that RNA is spliced or prevent a regulatory protein from binding to DNA. These consequences often depend on sequences located far from the affected gene, which is why it matters that the model retain context across a broad region.

AlphaGenome combines convolutional layers, which detect local patterns in the sequence, with transformers, an architecture capable of connecting distant positions. Based on that analysis, it predicts thousands of molecular properties: where genes start and end, how much RNA is produced, RNA splicing, DNA accessibility, contacts between regions of the genome and the binding of regulatory proteins.

One model versus specialized tools

DeepMind trained AlphaGenome on public data from consortia including ENCODE, GTEx, 4D Nucleome and FANTOM5, which experimentally measured gene regulation across hundreds of human and mouse cell types and tissues.

The company says its model outperformed the best external system in 22 of 24 prediction evaluations on DNA sequences. In tests designed to estimate the regulatory effect of variants, it matched or exceeded the best models in 24 of 26 evaluations. The comparison includes tools specialized in specific tasks; AlphaGenome’s bet is to bring those predictions together in a single system.

That unification may matter more than a one-off improvement in a results table. A lab studying a suspicious variant typically combines different programs to estimate gene expression, DNA accessibility or changes in splicing. DeepMind proposes obtaining those signals with a single API call by comparing predictions for the original sequence with those for the mutated sequence. According to the company, the calculation can be completed in one second.

The model follows in the footsteps of Enformer, another DeepMind system for predicting gene activity from sequence. It also complements AlphaMissense, which classifies variants in protein-coding regions. AlphaGenome broadens the focus to non-coding regions, where there are far more variants and fewer known rules for interpreting them.

From prioritizing mutations to designing DNA

DeepMind illustrates the system’s usefulness with mutations linked to T-cell acute lymphoblastic leukemia. AlphaGenome predicted that certain non-coding variants could activate the TAL1 gene by creating a binding motif for the MYB protein, reproducing a previously known disease mechanism. The value of the example is not that it discovered the case from scratch, but that it shows the model can connect a specific DNA change with a plausible gene and regulatory mechanism.

Potential applications include researching rare diseases, where an uncommon variant can have a major effect, and searching for therapeutic targets. It could also be useful in synthetic biology for designing sequences that activate a gene in a specific cell type, such as neurons, but not in other tissues.

The distinction between prediction and demonstration is worth preserving. The model learns from available measurements and offers hypotheses about what may happen in a cell; experimental validation will still be necessary, especially when a conclusion is intended to guide clinical research. In addition, more distant regulatory interactions and individual-specific effects remain difficult problems for models based solely on sequence.

AlphaGenome is available in preview through an API for non-commercial research. DeepMind plans to release the model later. If its results hold up outside benchmarks, it could reduce one of the most costly obstacles in modern genomics: deciding which of the millions of possible differences in DNA are worth taking to the lab.